Table 2.
Significant factors associated with severe COVID‐19 illnessa
| Coefficient | 95% CI | P | |
|---|---|---|---|
| Diabetes | 23.4 | 14.99‐31.7 | <.0001 |
| Malignancy | 23.4 | 9.9‐36.9 | .0007 |
| Cerebrovascular disease | 19.6 | 2.6‐36.6 | .02 |
| Hypertension | 5.1 | 1.1‐9.1 | .01 |
| Immunosuppressed | 53.9 | 31.3‐76.4 | <.0001 |
| Time from illness onset to first hospital admission, d | 0.4 | 0.1‐0.6 | .0008 |
| Shortness of breath | 5.4 | 4.1‐6.7 | <.0001 |
| Vomiting | 11.4 | 0.2‐22.7 | .05 |
| Abdominal pain | 24.7 | 17.4‐31.9 | <.0001 |
| Fatigue | 1.7 | 0.3‐3.0 | .01 |
| Chest pain | 4.5 | 1.8‐7.1 | .001 |
| Nausea | 8.8 | 0.2‐17.4 | .05 |
| Respiratory failure | 1.4 | 0.6‐2.3 | .001 |
| Lymphocyte count, g/L | −2.2 | −4.3‐(−0.2) | .04 |
| Neutrophil count, g/L | 0.6 | 0.2‐0.9 | .0008 |
| Albumin, µmol/L | −0.2 | −0.3‐(−0.1) | .0009 |
| C‐reactive protein, mg/L | 0.02 | 0.01‐0.04 | .007 |
Abbreviations: ATS, American Thoracic Society; CI, confidence interval; COVID‐19, coronavirus disease 2019; IDSA, Infectious Disease Society of America; WHO, World Health Organization.